Drug Trial Radar · NCT02301130
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Nov 26, 2014
Primary completion
Dec 8, 2017
Study completion Mar 5, 2018
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Nov 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Conditions
- Advanced Solid Tumors
Interventions
mogamulizumabBiological
Mogamulizumab will be administered intravenously (IV).
MEDI4736 (Durvalumab)Biological
MEDI4736 will be administered intravenously (IV).
tremelimumabBiological
Tremelimumab will be administered intravenously (IV).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects reporting adverse eventsTime frame: Screening through 90 days after the last dose of study medication
- Number of subjects reporting serious adverse eventsTime frame: Screening through 90 days after the last dose of study medication
- Percentage of subjects reporting serious adverse eventsTime frame: Screening through 90 days after the last dose of study medication
- Percentage of subjects reporting adverse eventsTime frame: Screening through 90 days after the last dose of study medication
- Number of subjects experiencing dose-limiting toxicityTime frame: First dose of study medications through 4 weeks after the last dose of study medication
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The Angeles Clinic
Los Angeles, California
UCLA Hematology & Oncology Clinic
Los Angeles, California
Yale Cancer Center
New Haven, Connecticut
H. Lee Moffitt Cancer Center
Tampa, Florida
Georgia Cancer Center
Augusta, Georgia
Memorial Sloan-Kettering Cancer Center
New York, New York
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.